Logo Logo
Switch Language to German
Lang, K.; Weber, K.; Quinkler, M.; Dietz, A. S.; Wallaschofski, H.; Hannemann, A.; Friedrichs, N.; Rump, L. C.; Heinze, B.; Fuss, C. T.; Quack, I.; Willenberg, H. S.; Reincke, M.; Allolio, B.; Hahner, S. (2016): Prevalence of Malignancies in Patients With Primary Aldosteronism. In: Journal of Clinical Endocrinology & Metabolism, Vol. 101, No. 4: pp. 1656-1663
Full text not available from 'Open Access LMU'.


Context: Primary aldosteronism (PA) is the most common cause of secondary hypertension. Aldosterone excess can cause DNA damage in vitro and in vivo. Single case reports have indicated a coincidence of PA with renal cell carcinoma and other tumors. However, the prevalence of benign and malignant neoplasms in patients with PA has not yet been studied. Patients and Design: In the multicenter MEPHISTO study, the prevalence of benign and malignant tumors was investigated in 335 patients with confirmed PA. Matched hypertensive subjects from the population-based Study of Health in Pomerania cohort served as controls. Results: Of the 335 PA patients, 119 (35.5%) had been diagnosed with a tumor at any time, and 30 had two or more neoplasms. Lifetime malignancy occurrence was reported in 9.6% of PA patients compared to 6.0% of hypertensive controls (P = .08). PA patients with a history of malignancy had higher baseline aldosterone levels at diagnosis of PA (P = .009), and a strong association between aldosterone levels and the prevalence of malignancies was observed (P = .03). In total, 157 neoplasms were identified in the PA patients;they were benign in 61% and malignant in 25% of the cases (14% of unknown dignity). Renal cell carcinoma was diagnosed in five patients (13% of all malignancies) and was not reported in controls. Conclusion: Compared to hypertensive controls, the prevalence of malignancies was positively correlated with aldosterone levels, tended to be higher in PA patients, but did not differ significantly.